The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy
Open accessAbstract
Background: Indoleamine 2,3-dioxygenase (IDO) catalyzes the rate-limiting step of tryptophan (Trp) degradation via the kynurenine (Kyn) pathway, which inhibits the proliferation of T cells and induces the apoptosis of T cells, leading to immune tolerance. Therefore, IDO has been considered as the most important mechanism for tumor cells to escape from immune response. Previous studies suggested that IDO might be involved in the progression of tumor and resistance to chemotherapy. Several preclinical and clinical studies have proven that IDO inhibitors can regulate IDO-mediated tumor immune escape and potentiate the effect of chemotherapy. Thus, the present study investigated the correlation between the clinical parameters, responses to chemotherapy, and IDO activity to provide a theoretical basis for the clinical application of IDO inhibitors to improve the suppression status and poor prognosis in cancer patients. Methods: The serum concentrations of Trp and Kyn were measured by high-performance liquid chromatography in 252 patients with stage IIIB or IV non-small-cell lung cancer, and 55 healthy controls. The IDO activity was determined by calculating the serum Kyn-to-Trp (Kyn/Trp) ratio. Results: The IDO activity was significantly higher in the lung cancer patients than in the controls (median 0.0389 interquartile range [0.0178–0.0741] vs 0.0111 [0.0091–0.0133], respectively; P <0.0001). In addition, patients with adenocarcinoma had higher IDO activity than patients with nonadenocarcinoma (0.0449 [0.0189–0.0779] vs 0.0245 [0.0155–0.0563], respectively; P =0.006). Furthermore, patients with stage IIIB disease had higher IDO activity than patients with stage IV disease (0.0225 [0.0158–0.0595] vs 0.0445 [0.0190–0.0757], respectively; P =0.012). The most meaningful discovery was that there was a significant difference between the partial response (PR) patients and the stable disease (SD) and progressive disease (PD) patients (0.0240 [0.0155–0.0381] vs 0.0652 [0.0390–0.0831] vs 0.0868 [0.0209–0.0993], respectively, P <0.0001). Conclusion: IDO activity was increased in lung cancer patients. Higher IDO activity correlated with histological types and disease stages of lung cancer patients, induced the cancer cells’ resistance to chemotherapy, and decreased the efficacy of chemotherapy. Keywords: advanced non-small-cell lung cancer, indoleamine 2,3-dioxygenase, immune escape, chemotherapy response, tumor immunotherapy
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NSCLC patients have increased tryptophan catabolism compared with the general population, leading to higher serum kynurenine, which is associated with advanced stage at diagnosis, poor prognosis and chemotherapy resistance.
“Compared with the general population, patients with NSCLC have increased tryptophan catabolism, which leads to higher kynurenine serum concentrations and has been associated with advanced stage disease at diagnosis, an unfavourable prognosis and resistance to chemotherapy148,149.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003 · see citing works
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works
<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203 · see citing works
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,087 · see citing works
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341 · see citing works
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · see citing works
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature reviews. Immunology · doi:10.1038/nri1806 · Cited by 2,075 · see citing works
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · see citing works
Auperin, A., Pechoux, C. L., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J. S. A., Clamon, G. H., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,882 · see citing works
Govindan, R., Page, N. C., Morgensztern, D., Read, W. L., Tierney, R. M., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,844 · see citing works
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D., Shafizadeh, E., Attwood, J., Bondarev, I., Pashine, A., & Mellor, A. (1999) · Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,721 · see citing works
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works
Huber, C., Batchelor, J. R., Fuchs, D., Hausen, A., Lang, A. H., Niederwieser, D. W., Reibnegger, G. J., Swetly, P., Troppmair, J., & WACHTER, H. (1984) · The Journal of Experimental Medicine · doi:10.1084/jem.160.1.310 · Cited by 1,084 · see citing works
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,074 · see citing works
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064 · see citing works
Pfefferkorn, E. (1984) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.81.3.908 · Cited by 870 · see citing works
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852 · see citing works
Hwu, P., Du, M. X., Lapointe, R., Do, M., Taylor, M. W., & Young, H. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3596 · Cited by 742 · see citing works
Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?
Mellor, A. L., & Munn, D. H. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01520-0 · Cited by 647 · see citing works
Mishima, S., Nozaki, Y., Mikami, S., Kihira, E., Iikura, M., Koketsu, R., Sugiyama, H., Masuda, T., Kaname, H., Egami, Y., et al. (2015) · Case Reports in Gastroenterology · doi:10.1159/000381140 · Cited by 631 · see citing works
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614 · see citing works
Yu, J., Du, W., Fang, Y., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 608 · see citing works
Self-citationHou, D., Muller, A. J., Sharma, M. D., DuHadaway, J. B., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586 · see citing works
Wainwright, D. A., Balyasnikova, I. V., Chang, A. L., Ahmed, A. U., Moon, K., Auffinger, B., Tobias, A. L., Han, Y., & Lesniak, M. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2130 · Cited by 470 · see citing works
Chen, W., Liang, X., Peterson, A. J., Munn, D. H., & Blazar, B. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5396 · Cited by 453 · see citing works
Sica, A., Saccani, A., Bottazzi, B., Polentarutti, N., Vecchi, A., Damme, J. V., & Mantovani, A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.762 · Cited by 423 · see citing works
Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
Awad, M. M., Katayama, R., McTigue, M. A., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 421 · see citing works
Curti, A., Pandolfi, S., Valzasina, B., Aluigi, M., Isidori, A., Ferri, E., Salvestrini, V., Bonanno, G., Rutella, S., Durelli, I., et al. (2006) · Blood · doi:10.1182/blood-2006-07-036863 · Cited by 396 · see citing works
Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N., Yanaihara, N., Yamada, K., Takikawa, O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2671 · Cited by 391 · see citing works
Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase.
Takikawa, O., Yoshida, R., Kido, R., et al. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35696-x · Cited by 377 · see citing works
Jackman, D. M., Miller, V. A., Cioffredi, L., Yeap, B. Y., Janne, P. A., Riely, G. J., Ruiz, M. I. G., Giaccone, G., Sequist, L. V. D., & Johnson, B. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0888 · Cited by 375 · see citing works
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A. B., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 366 · see citing works
Théate, I., van Baren, N., Pilotte, L., Moulin, P., Larrieu, P., Renauld, J., Hervé, C., Gutierrez-Roelens, I., Marbaix, É., Sempoux, C. L., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0137 · Cited by 366 · see citing works
Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses
Mellor, A. L., Keskin, D. B., Johnson, T. S., Chandler, P., & Munn, D. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3771 · Cited by 348 · see citing works
EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib
Hanna, N. H. (2006) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)70161-1 · Cited by 342 · see citing works
Immune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325 · see citing works
Scagliotti, G. V., Parikh, P. M., von Pawel, J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02544 · Cited by 273 · see citing works
Chung, D. J., Rossi, M., Romano, E., Ghith, J., Yuan, J. D., Munn, D. H., & Young, J. W. (2009) · Blood · doi:10.1182/blood-2008-11-191197 · Cited by 264 · see citing works
Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer
Suzuki, Y., Suda, T., Furuhashi, K., Suzuki, M., Fujie, M., Hahimoto, D., Nakamura, Y., Inui, N., Nakamura, H., & Chida, K. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.001 · Cited by 263 · see citing works
Schefold, J. C., Zeden, J.-P., Fotopoulou, C., von Haehling, S., Pschowski, R., Hasper, D., Volk, H., Schuett, C., & Reinke, P. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn739 · Cited by 256 · see citing works
Kim, J. W., Nam, K. H., Ahn, S.-H., Park, D. J., Kim, H., Kim, S. H., Chang, H. K., Lee, J., Kim, Y. J., Lee, H. S., et al. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0440-5 · Cited by 249 · see citing works
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., Takahashi, N. K., Terauchi, M., Nawa, A., Nomura, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603477 · Cited by 247 · see citing works
Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M. C., Paz-Ares, L. G., Reck, M., Smit, E. F., Syrigos, K., Stahel, R. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu123 · Cited by 244 · see citing works
Huang, A., Fuchs, D., Widner, B., Glover, C., Henderson, D. C., & Allen-Mersh, T. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600336 · Cited by 241 · see citing works
Ino, K., Yamamoto, E., Shibata, K., Kajiyama, H., Yoshida, N., Terauchi, M., Nawa, A., Nagasaka, T., Takikawa, O., & Kikkawa, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4144 · Cited by 241 · see citing works
Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma.
Ozaki, Y., EDELSTEIN, M. P., & Duch, D. S. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1242 · Cited by 240 · see citing works
Inaba, T., Ino, K., Kajiyama, H., Yamamoto, E., Shibata, K., Nawa, A., Nagasaka, T., Akimoto, H., Takikawa, O., & Kikkawa, F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.07.015 · Cited by 217 · see citing works
Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients
Weinlich, G., Murr, C., Richardsen, L., Winkler, C., & Fuchs, D. (2006) · Dermatology · doi:10.1159/000096906 · Cited by 197 · see citing works
More Rapid Method for Simultaneous Measurement of Tryptophan and Kynurenine by HPLC
Laich, A., Neurauter, G., Widner, B., & Fuchs, D. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.3.579 · Cited by 193 · see citing works
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
Pan, K., Wang, H., Chen, M.-S., Zhang, H.-K., Weng, D., Zhou, J., Huang, W. C., Li, X. H., Song, H.-F., & Xia, J. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0395-1 · Cited by 169 · see citing works
Astigiano, S., Morandi, B., Costa, R., Mastracci, L., D'Agostino, A., Ratto, G. B., Melioli, G., & Frumento, G. (2005) · Neoplasia · doi:10.1593/neo.04658 · Cited by 161 · see citing works
Halak, B. K., Maguire, H., & Lattime, E. C. (1999) · PubMed · Cited by 158 · see citing works
Dai, F., Liu, L.-X., Che, G., Yu, N., Pu, Q., Zhang, S., Ma, J., Ma, L., & You, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-220 · Cited by 151 · see citing works
Witkiewicz, A., Williams, T. K., Cozzitorto, J. A., Durkan, B., Showalter, S. L., Yeo, C. J., & Brody, J. R. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.12.014 · Cited by 150 · see citing works
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Raval, R. R., Sharabi, A. B., Walker, A. J., Drake, C. G., & Sharma, P. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-14 · Cited by 140 · see citing works
Chen, J.-Y., Li, C., Kuo, C.-C., Tsai, K. K., Hou, M., & Hung, W.-C. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0410-1 · Cited by 137 · see citing works
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy
Vanderstraeten, A., Luyten, C., Verbist, G., Tuyaerts, S., & Amant, F. C. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1537-8 · Cited by 127 · see citing works
Folgiero, V., Goffredo, B. M., Filippini, P., Masetti, R., Bonanno, G., Caruso, R., Bertaina, V., Mastronuzzi, A., Gaspari, S., Zecca, M., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1504 · Cited by 110 · see citing works
Neopterin Is an Independent Prognostic Variable in Females with Breast Cancer
Murr, C., Bergant, A. M., Widschwendter, M., et al. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.11.1998 · Cited by 109 · see citing works
Chamuleau, M. E. D., van de Loosdrecht, A. A., Hess, C. J., Janssen, J. J. W. M., Zevenbergen, A., Delwel, R., Valk, P. J. M., Löwenberg, B., & Ossenkoppele, G. J. (2008) · Haematologica · doi:10.3324/haematol.13113 · Cited by 104 · see citing works
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
Speeckaert, R., Vermaelen, K., van Geel, N., Autier, P., Lambert, J., Haspeslagh, M., Gele, M. V., Thielemans, K., Neyns, B., Roche, N. A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.007 · Cited by 100 · see citing works
Corm, S., Berthon, C., Imbenotte, M., Biggio, V., Lhermitte, M., Dupont, C., Briche, I., & Quesnel, B. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.014 · Cited by 97 · see citing works
Takao, M., Okamoto, A., Nikaido, T., Urashima, M., Takakura, S., Saito, M., Saito, M., Okamoto, S., Takikawa, O., Sasaki, H., et al. (2007) · Oncology Reports · doi:10.3892/or.17.6.1333 · Cited by 97 · see citing works
Watanabe, K., Emoto, N., Hamano, E., Sunohara, M., Kawakami, M., Kage, H., Kitano, K., Nakajima, J., Goto, A., Fukayama, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26254 · Cited by 96 · see citing works
Jia, Y., Wang, H., Wang, Y., Wang, T., Wang, M., Ma, M., Duan, Y., Meng, X., & Liu, L. (2015) · International Journal of Cancer · doi:10.1002/ijc.29481 · Cited by 95 · see citing works
Self-citationNeopterin as a prognostic indicator in patients with carcinoma of the uterine cervix.
Reibnegger, G. J., Bichler, A., Dapunt, O., et al. (1986) · PubMed · Cited by 94 · see citing works
Maeda, R., Yoshida, J., Ishii, G., et al. (2011) · CHEST Journal · doi:10.1378/chest.10-3279 · Cited by 89 · see citing works
Clinical significance of neopterin for prognosis and follow-up in ovarian cancer.
Reibnegger, G. J., Hetzel, H., Fuchs, D., Fuith, L. C., Hausen, A., Werner, E. R., & Wächter, H. (1987) · PubMed · Cited by 88 · see citing works
Ninomiya, S., Hara, T., Tsurumi, H., Hoshi, M., Kanemura, N., Goto, N., Kasahara, S., Shimizu, M., Ito, H., Saito, K., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1093-z · Cited by 87 · see citing works
Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer
Karanikas, V., Ζαμανάκου, Μ., Kerenidi, T., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.8.4446 · Cited by 86 · see citing works
Pawlak, K., Brzόsko, S., Myśliwiec, M., & Pawlak, D. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.10.002 · Cited by 84 · see citing works
Tryptophan degradation in patients with gynecological cancer correlates with immune activation
Schroecksnadel, K., Winkler, C., Fuith, L. C., & Fuchs, D. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.10.033 · Cited by 84 · see citing works
Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy
Cooke, D. T., Nguyen, D. V., Yang, Y., et al. (2010) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2010.05.025 · Cited by 83 · see citing works
Yu, J., Sun, J., Wang, S. E., Li, H., Cao, S., Cong, Y., Liu, J., & Ren, X. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/469135 · Cited by 76 · see citing works
New modalities of cancer treatment for NSCLC: focus on immunotherapy
Davies, M. (2014) · Cancer Management and Research · doi:10.2147/cmar.s57550 · Cited by 72 · see citing works
Choe, J., Yun, J. Y., Jeon, Y., Kim, S. H., Park, G., Huh, J. R., Oh, S., & Kim, J. E. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-335 · Cited by 72 · see citing works
de Jong, R. A., Nijman, H. W., Boezen, H. M., Volmer, M., ten Hoor, K. A., Krijnen, J., van der Zee, A. G. J., Hollema, H., & Kema, I. P. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31822017fb · Cited by 72 · see citing works
Tryptophan degradation in women with breast cancer: a pilot study
Lyon, D., Walter, J. M., Starkweather, A. R., Schubert, C. M., & McCain, N. L. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-156 · Cited by 71 · see citing works
Inaba, T., Ino, K., Kajiyama, H., Shibata, K., Yamamoto, E., Kondo, S., Umezu, T., Nawa, A., Takikawa, O., & Kikkawa, F. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.02.028 · Cited by 70 · see citing works
Yoshikawa, T., Hara, T., Tsurumi, H., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01393.x · Cited by 70 · see citing works
Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma
Urakawa, H., Nishida, Y., Nakashima, H., Shimoyama, Y., Nakamura, S., & Ishiguro, N. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9290-7 · Cited by 68 · see citing works
Chevolet, I., Speeckaert, R., Haspeslagh, M., Neyns, B., Krüse, V., Schreuer, M. S., Gele, M. V., van Geel, N., & Brochez, L. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13100 · Cited by 68 · see citing works
Bonanno, G., Mariotti, A., Procoli, A., Folgiero, V., Natale, D., Rosa, L. D., Majolino, I., Novarese, L., Rocci, A., Gambella, M., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-247 · Cited by 67 · see citing works
Neopterin and prognosis in patients with adenocarcinoma of the colon.
Weiss, G., Kronberger, P., Conrad, F., Bodner, E., WACHTER, H., & Reibnegger, G. J. (1993) · PubMed · Cited by 61 · see citing works
Sperner‐Unterweger, B., Neurauter, G., Klieber, M., Kurz, K., Meraner, V., Zeimet, A. G., & Fuchs, D. (2010) · Immunobiology · doi:10.1016/j.imbio.2010.07.010 · Cited by 53 · see citing works
Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma
Masaki, A., Ishida, T., Maeda, Y., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2275 · Cited by 52 · see citing works
Hoshi, M., Ito, H., Fujigaki, H., Takemura, M., Takahashi, T., Tomita, E., Ohyama, M., Tanaka, R., Saito, K., & Seishima, M. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.05.023 · Cited by 52 · see citing works
Ou, X., Cai, S., Liu, P., Zeng, J., He, Y., Wu, X., & Du, J. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0315-9 · Cited by 49 · see citing works
Kato, A., Suzuki, Y., Suda, T., Suzuki, M., Fujie, M., Takita, T., Furuhashi, M., Maruyama, Y., Chida, K., & Hishida, A. (2010) · Hemodialysis international. International Symposium on Home Hemodialysis · doi:10.1111/j.1542-4758.2010.00464.x · Cited by 47 · see citing works
Zhang, G., Liu, W., Zhang, L., Wang, J., Kuang, M.-H., Liu, P., Lin, Y., Dai, S., & Du, J. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/384726 · Cited by 46 · see citing works
Liu, X.-Q., Lu, K., Feng, L., Ding, M., Gao, J., Ge, X., & Wang, X. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.804917 · Cited by 45 · see citing works
Immunotherapy in Acute Myeloid Leukemia
Arpinati, M., & Curti, A. (2013) · Immunotherapy · doi:10.2217/imt.13.152 · Cited by 33 · see citing works
Bronchial resection margin length and clinical outcome in non-small cell lung cancer
Tomaszek, S. C., Kim, Y. S., Cassivi, S. D., et al. (2011) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2011.02.042 · Cited by 31 · see citing works
Zeng, J., Cai, S., Yi, Y., He, Y., Wang, Z., Jiang, G., Li, X., & Du, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2476 · Cited by 29 · see citing works
Self-citationIncreased tryptophan degradation in patients with bronchus carcinoma
Engin, A. B., Özkan, Y., Fuchs, D., et al. (2009) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2009.01122.x · Cited by 28 · see citing works
Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
Page, D. B., Bourla, A. B., Daniyan, A. F., Naidoo, J., Smith, E. L., Smith, M. M., Friedman, C. F., Khalil, D. N., Funt, S. A., Shoushtari, A. N., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0072-2 · Cited by 27 · see citing works
Immunoepigenetics: the unseen side of cancer immunoediting
Germenis, A. E., & Karanikas, V. (2006) · Immunology and Cell Biology · doi:10.1038/sj.icb.7100006 · Cited by 24 · see citing works
Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas
Liu, J., Lu, G., Fuai, T., Liu, Y., & Cui, G. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0846-3 · Cited by 24 · see citing works
[Study of indoleamine 2,3-dioxygenase expression in patients of esophageal squamous cell carcinoma].
Sakurai, K., Enomoto, K., Amano, S., et al. (2004) · PubMed · Cited by 19 · see citing works
Serum Kynurenic Acid: Possible Association with Invasiveness of Non-small Cell Lung Cancer
Sagan, D., Kocki, T., Kocki, J., et al. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.9.4741 · Cited by 14 · see citing works
Chen, W., Liang, X., Peterson, A. J., et al. (2007) · Blood · doi:10.1182/blood.v110.11.1344.1344 · Cited by 11 · see citing works
Xie, Q., Wang, L., Zhu, B., et al. (2008) · PubMed · doi:10.3779/j.issn.1009-3419.2008.01.025 · Cited by 10 · see citing works
Dubinett, S. M., & Sharma, S. P. (2009) · Immunotherapy · doi:10.2217/imt.09.56 · Cited by 8 · see citing works
[Study of indoleamine 2,3-dioxygenase expression in patients of thyroid cancer].
Sakurai, K., Fujisaki, S., Nagashima, S., et al. (2011) · PubMed · Cited by 7 · see citing works
A phase I study of 1-methyl-D-tryptophan in combination with docetaxel in metastatic solid tumors.
Jackson, E., Minton, S. E., Ismail-Khan, R. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.tps2620 · Cited by 7 · see citing works
吉川, 武. (2010) · Institutional Repositories DataBase (IRDB) · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141 · see citing works
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Botticelli, A., Cerbelli, B., Lionetto, L., Zizzari, I., Salati, M., Pisano, A., Federica, M., Simmaco, M., Nuti, M., & Marchetti, P. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1595-3 · Cited by 124 · see citing works
- Authors
- Wang, Y., Hu, G.-F., & Wang, Z.
- Affiliations
- University of Jinan (CN)
- Shandong University (CN)
- Corresponding author
- Wang, Zhehai
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-07
- Volume
- Volume 10
- Pages
- 3557-3566
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC5530847
- OpenAlex
- W2737710038
- Cited by
- 21
- References
- 108
- Citations by year
- 2025: 3 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 2
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- non-small cell lung cancer, indoleamine 2,3-dioxygenase, kynurenine pathway, tryptophan, kynurenine/tryptophan ratio, tumor immune evasion, chemotherapy response, IDO inhibitors, adenocarcinoma, tumor stage, prognostic factors, immunosuppression, T cell apoptosis, immune tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
